Abstract
Nicotine is well known for its deleterious effects on human health, and it has long been known that nicotine interacts with the stress axis in both man and in laboratory animals. Nicotine also has beneficial effects upon cognition, and an emerging literature has demonstrated that it may play a protective or palliative role in diseases such as Alzheimer’s disease and schizophrenia. Recent advances have permitted scientists to identify the specific subtypes of nicotinic receptors responsible for the drugs varied physiological effects. The α7 subunit of the nicotinic acetylcholine receptor (NAchRα7), has been identified as a significant mediator of nicotine ’ s interactions with the stress axis and human disease. The NAchRα7 has also been shown to have neuroprotective effects via multiple pathways, making it a logical target for the treatment of a number of brain disorders.
Keywords: Nicotinic Receptors, stress, HPA axis, hippocampus, acetylcholin e, corticosteroid, brain disorder, NAchRα7, nicotine interact, GRE
Current Drug Targets
Title:Stress and the α7 Nicotinic Acetylcholine Receptor
Volume: 13 Issue: 5
Author(s): Richard G. Hunter
Affiliation:
Keywords: Nicotinic Receptors, stress, HPA axis, hippocampus, acetylcholin e, corticosteroid, brain disorder, NAchRα7, nicotine interact, GRE
Abstract: Nicotine is well known for its deleterious effects on human health, and it has long been known that nicotine interacts with the stress axis in both man and in laboratory animals. Nicotine also has beneficial effects upon cognition, and an emerging literature has demonstrated that it may play a protective or palliative role in diseases such as Alzheimer’s disease and schizophrenia. Recent advances have permitted scientists to identify the specific subtypes of nicotinic receptors responsible for the drugs varied physiological effects. The α7 subunit of the nicotinic acetylcholine receptor (NAchRα7), has been identified as a significant mediator of nicotine ’ s interactions with the stress axis and human disease. The NAchRα7 has also been shown to have neuroprotective effects via multiple pathways, making it a logical target for the treatment of a number of brain disorders.
Export Options
About this article
Cite this article as:
Richard G. Hunter , Stress and the α7 Nicotinic Acetylcholine Receptor, Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800398982
DOI https://dx.doi.org/10.2174/138945012800398982 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medical Music Therapy Based on Baby Science (Baby-Science-Based Music Therapy) and Assistive Technology for Children
Current Pediatric Reviews Autophagy Dysfunction and its Link to Alzheimer’s Disease and Type II Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Prion Function and Pathophysiology in Non-Mammalian Models
Current Molecular Medicine The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Flavonoids Health Benefits and Their Molecular Mechanism
Mini-Reviews in Medicinal Chemistry Dysregulated Pathway Identification of Alzheimer's Disease Based on Internal Correlation Analysis of Genes and Pathways
Combinatorial Chemistry & High Throughput Screening Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future
Current Pharmaceutical Design In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Dehydroepiandrosterone (DHEA): A Steroid with Multiple Effects. Is there Any Possible Option in the Treatment of Critical illness?
Current Medicinal Chemistry Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Synthesis of Chiral 2-(6,8-dichloro-4-methyl-1,1,3-trioxo-3,4-dihydro-1H-1λ6-benzo[1,2,4]thiadiazin-2-yl) Carboxylic Acids Derived from Enantiomeric Amino Acids
Letters in Organic Chemistry Editorial (Thematic Issue: TBD - New Developments in the Medicinal Chemistry and Drug Discovery of Agents for Infectious Diseases)
Current Topics in Medicinal Chemistry Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Essential Oils and Pure Volatile Compounds as Potential Drugs in Alzheimer’s Disease Therapy: An Updated Review of the Literature
Current Pharmaceutical Design